Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction

Patent publication in Europe strengthens Clearmind’s global IP position and advances strategic focus on addiction treatment

Vancouver, Canada, May 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today the official publication of a European patent application by the European Patent Office (EPO).

Read more at globenewswire.com